Sensex Jolt | Guidance Downgraded Significantly: Novo Nordisk (NVO.US) Plummets Over 20%

According to our financial news app, on Tuesday, Novo Nordisk (NVO.US) plummeted over 20% at the opening, setting a new low in nearly two and a half years, at $54.60 per share. On the news side, Novo Nordisk suddenly released guidance warning, significantly downgrading its sales and operating profit growth expectations for 2025, primarily due to Wegovy's underwhelming performance. Novo Nordisk stated that its sales growth expectations, calculated in fixed exchange rates, have been lowered from 13%-21% to 8%-14%, while operating profit growth expectations have been lowered from 16%-24% to 10%-16%.

The company noted that Wegovy's penetration rate in cash payment channels is lower than expected, mainly due to the continued impact of "unauthorized and illegal mass counterfeit drugs". Additionally, its flagship diabetes medication Ozempic faces increased pressure from intensified competition on the US market. Analysts had previously predicted Novo Nordisk's full-year sales growth at 16.6%.